neoplasia

Imiquimod (R 837) 是一种免疫反应修饰剂，可作为 toll 样受体7 激动剂。它有抗病毒和抗肿瘤作用，可研究外生殖器、肛周疣、癌症和 COVID-19。

Suberoyl bis-hydroxamic acid (SBHA) 是一种竞争性且可透过细胞的HDAC1和HDAC3抑制剂，ID50值分别为 0.25 μM 和 0.30 μM。它使肿瘤细胞易于凋亡并促进线粒体凋亡途径，可研究甲状腺髓样癌。

Xinidamine (BRN 0891979) 具有抗肿瘤活性，可用于研究良性前列腺增生、黄斑变性和前列腺上皮内瘤 。Xinidamine 对PWR-1E 细胞的增殖具有抑制作用，IC50为4μM。

ABI-1968 PM 是ABI-1968的一种衍生物。ABI-1968是一种细胞凋亡刺激剂，是一种病毒复制抑制剂。ABI-1968可用于研究宫颈上皮内瘤样病变、乳头状瘤病毒感染和鳞状上皮内病变。

Monensin is an antiprotozoal agent produced by Streptomyces cinnamonensis. It has an inhibitory effect on the Wnt β-catenin signaling cascade. Monensin is a prospective anticancer drug for the therapy of neoplasia with deregulated Wnt signaling.

Enzomenib (DSP5336) 是一种针对多发性内分泌腺瘤 (MEN) 基因所编码的menin蛋白的抑制剂。它能阻断menin蛋白与混合谱系白血病 (MLL) 融合蛋白之间的相互作用，应用于血液系统恶性肿瘤的研究领域。

INCB16562 is a novel, selective, and orally bioavailable small-molecule inhibitor of JAK1 and JAK2 markedly selective over JAK3. Treatment of myeloma cells with INCB16562 potently inhibited interleukin-6 (IL-6)-induced phosphorylation of STAT3. INCB16562 abrogated the protective effects of recombinant cytokines or bone marrow stromal cells and sensitized myeloma cells to cell death by exposure to dexamethasone, melphalan, or bortezomib. Oral administration of INCB16562 antagonized the growth of myeloma xenografts in mice and enhanced the antitumor activity of relevant agents in combination studies. INCB16562 is a potent JAK1 2 inhibitor and that mitigation of JAK STAT signaling by targeting JAK1 and JAK2 will be beneficial in the treatment of myeloma patients, particularly in combination with other agents. ( source: Neoplasia. 2010 Jan;12(1):28-38. ).